The STOP-NIDDM trial: An international study on the efficacy of an α- glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: Rationale, design, and preliminary screening data

Diabetes Care

Volumn 21, Issue 10, 1998, Pages 1720-1725

  Chiasson, Jean Louis ^a,g   Gomis, Ramon ^c   Hanefeld, Markolf ^d   Josse, Robert G ^b   Karasik, Avraham ^e   Laakso, Markku ^f  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e SHEBA MEDICAL CENTER   (Israel)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g Research Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; INSULIN; METFORMIN; PLACEBO; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; TREATMENT OUTCOME;

ACARBOSE; BLOOD PRESSURE; CANADA; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INTERNATIONAL COOPERATION; ISRAEL; MALE; MASS SCREENING; MIDDLE AGED; PREGNANCY; RESEARCH DESIGN; RISK FACTORS; TIME FACTORS; TRISACCHARIDES;

EID: 0031682113     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.10.1720     Document Type: Article

References (31)

1. Wetterhall SF, Olson DR, DeStefano F, Stevenson JM, Ford ES, German RR, Will JC, Newman JM, Sepe SJ, Vinicor F: Trends in diabetes and diabetic complications, 1980-1987. Diabetes Care 15:960-967, 1992
2. Rubin RJ, Altman WM, Mendelson DN: Health care expenditures for people with diabetes mellitus. 1992. J Clin Endocrinol Metab 78:809A-809F, 1994
3. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
4. World Health Organization: Prevention of Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1994 (Tech. Rep. Ser., no. 844)
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
6. King H, Rewers M, WHO Ad Hoc Diabetes Reporting Group: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 16:157-177, 1993
7. Harris MI: Impaired glucose tolerance: prevalence and conversion to NIDDM. Diabet Med 13 (Suppl. 2):S9-S11, 1996
8. Donahue RP, Orchard TJ: Diabetes mellitus and macrovascular complications: an epidemiological perspective. Diabetes Care 15:1141-1155, 1992
9. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
10. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368, 1992
11. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity Diabetes Care 13:610-630, 1990
12. Dowse GK, Zimmet PZ, King H: Relationship between prevalence of impaired glucose tolerance and NIDDM in a population. Diabetes Care 14:968-974, 1991
13. Chiasson J-L, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TMS: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19:1190-1193, 1996
14. Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 121:928-935, 1994
15. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500-1506, 1988
16. Bergman RN, Prager R, Volund A, Olefsky JM: Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79:790-800, 1987
17. Finegood DT, Hramiak IM, Dupré J: A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes J Clin Endocrinol Metab 70:1538-1549, 1990
18. Dawson KG, McKenzie JK, Ross SA, Chiasson J-L, Hamet P: Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes. CMAJ 149:821-826, 1993
19. Carruthers SG, Larochelle P, Haynes RB, Petrasovits A, Schiffrin EL: Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. CMAJ 149:289-293, 1993
20. Chan JCN, Yeung VTF, Leung DHY, Tomlinson B, Nicholls MG, Cockram CS: The effects of enalopril and nifedipine on carbohydrate and lipid metabolism in NIDDM. Diabetes Care. 17:859-862, 1994
21. Cole RA, Soeldner JS, Dunn PJ, Bunn HF: A rapid method for the determination of glycosylated hemoglobins using high pressure liquid chromatography Metabolism 27:289-301, 1978
22. Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray IP, Luzio SD, Owens DR, Schneider AE, Siddle K, Temple RC, Hales CN: Sensitive and specific two-site immunoradiometric assays to human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 260:535-541, 1989
23. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 28:1379-1388, 1982
24. Friedewald WT, Levy RI, Fredrickson DS: Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
25. DeMetz DL, Lan KKG: Interim analysis: the alpha spending function approach. Stat Med 13:1341-1359, 1994
26. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Harris MI: Prevention strategies for non-insulin-dependent diabetes mellitus: an economic perspective. In Diabetes Mellitus. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott-Raven, 1996, p. 621-630
27. Pan X, Li G, Hu Y-H, Wang J, Yang W, Zuo A, Ze H, Lin J, Xiao J-Z, Cao H, Liu P-A, Jiang X, Jiang Y, Wang J, Zheng H, Zhang H, Benneti PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
28. Mykkänen L, Laakso M, Uusitupa M, Pyorala K: Prevalence of diabetes and impaired glucose tolerance in elderly subjects and their association with obesity and family history of diabetes. Diabetes Care 13:1099-1105, 1990
29. Burchfiel CM, Hamman RF, Marshall JA, Baxter J, Kahn LB, Amirani JJ: Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study. Am J Epidemiol 131:57-70, 1990
30. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41:202-208, 1992
31. Gerstein HC, Yusuf S: Dysglycaemia and risk of cardiovascular disease. Lancet 347:949-950, 1996